Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Belviq
Pharma
Eisai ends lorcaserin development in Dravet syndrome
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin.
Fraiser Kansteiner
Nov 18, 2024 10:18am
Coronavirus, AZ, vadadustat and more—FiercePharmaAsia
Feb 21, 2020 9:55am
Eisai will pull Belviq off U.S. shelves on cancer concerns
Feb 14, 2020 9:32am
ESC need-to-know: Xarelto, tafamidis, Entresto and more
Aug 27, 2018 12:10pm
FiercePharmaAsia—Pfizer, China-India alliance, Sinovant and more
Jul 20, 2018 9:58am
Eisai obesity drug Belviq picks up heart-safety edge
Jul 18, 2018 10:28am
